Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
CSL paidMXN6,626 Mil more to buy back shares than it received from issuing new shares.
It spentMXN5,114 Mil paying down its debt.
It paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentMXN16,943 Mil paying cash dividends to shareholders.
It spentMXN900 Mil on other financial activities.
In all, CSLspentMXN29,583 Mil on financial activities for the
six
months ended in Dec. 2025.
CSL (MEX:CSL N) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
CSL's issuance of stock for the
six
months ended in Dec. 2025 was MXN324 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
CSL's repurchase of stock for the
six
months ended in Dec. 2025 was MXN-6,950 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
CSL's net issuance of debt for the
six
months ended in Dec. 2025 was MXN-5,114 Mil.
CSL spentMXN5,114 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
CSL's net issuance of preferred for the
six
months ended in Dec. 2025 was MXN0 Mil.
CSL paidMXN0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
CSL's cash flow for dividends for the
six
months ended in Dec. 2025 was MXN-16,943 Mil.
CSL spentMXN16,943 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
CSL's other financing for the
six
months ended in Dec. 2025 was MXN-900 Mil.
CSL spentMXN900 Mil on other financial activities.
CSL Cash Flow from Financing Related Terms
CSL Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for CSL's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
CSL's Cash from Financing for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was MXN-29,583 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN-29,583 Mil mean?
CSL (MEX:CSL N) has a Cash Flow from Financing of MXN-29,583 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CSL and its competitors.
Is CSL's Cash Flow from Financing too high?
CSL's current Cash Flow from Financing is MXN-29,583 Mil. Overall, CSL has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does CSL's Cash Flow from Financing compare to VRTX and REGN?
CSL's Cash Flow from Financing of MXN-29,583 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CSL and its competitors. CSL's current Cash Flow from Financing is MXN-29,583 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
CSL (MEX:CSL N) has a current Cash Flow from Financing of MXN-29,583 Mil. The stock's GF Value™ is MXN4,856.14, compared to a current price of MXN2,081.30 — trading 57.1% below its estimated fair value. The current Cash Flow from Financing is MXN-29,583 Mil. CSL's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For CSL (MEX:CSL N), the current Cash Flow from Financing is MXN-29,583 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (MEX:CSL N) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of MXN2,081.30 is trading 57.1% below its estimated GF Value™ of MXN4,856.14.
Key valuation signals for MEX:CSL N:
Cash Flow from Financing: MXN-29,583 Mil
GF Value™: MXN4,856.14 vs. price of MXN2,081.30 (57.1% below fair value)
No single metric tells the full story. See the MEX:CSL N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
78GF Score
Get the complete analysis for MEX:CSL N
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CSL N has been successfully added to your 
